Carlo Lazzaro, Giovanna Esposito, Anna Cantarutti, Francesco Parazzini, Giovanni Corrao, Matteo Franchi, Fabio Parazzini
{"title":"Managing severe gestational hypertension in Italy: a cost description.","authors":"Carlo Lazzaro, Giovanna Esposito, Anna Cantarutti, Francesco Parazzini, Giovanni Corrao, Matteo Franchi, Fabio Parazzini","doi":"10.1080/14737167.2026.2718416","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gestational hypertension (GH) is a common complication that affects approximately 5% of pregnancies worldwide.</p><p><strong>Research design and methods: </strong>Presenting a model-based cost description of managing severe GH in inward setting following the Italian National Health Service (INHS) perspective. Epidemiological data on pregnancies and severe GH were obtained from Lombardy region and extrapolated to national level for 2024 (last available year). Health care resources for managing severe GH patients aged 20-49 years, identified and quantified according to literature and expert' opinion, were valued through INHS tariffs (2025 values). One-way and scenario sensitivity analyses tested the robustness of the baseline findings.</p><p><strong>Results: </strong>375,553 pregnancies and 1928 episodes of severe GH needing hospitalization (0.51% of all pregnancies) were estimated for Italy in 2024. The overall average cost of managing a severe GH episode reaches €752.64. Inward hospitalization (€454.23) is the main cost-driver (60.04% of the total), as confirmed by one-way and scenario sensitivity analyses.</p><p><strong>Conclusion: </strong>As reported in research conducted in other countries, inward hospitalization is both essential and the main cost-driver for the optimal management of severe GH. Outpatient programmes aimed at identifying and following-up GH patients before the disease requires hospitalization should be considered by INHS policymakers.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":2.2000,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2026.2718416","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gestational hypertension (GH) is a common complication that affects approximately 5% of pregnancies worldwide.
Research design and methods: Presenting a model-based cost description of managing severe GH in inward setting following the Italian National Health Service (INHS) perspective. Epidemiological data on pregnancies and severe GH were obtained from Lombardy region and extrapolated to national level for 2024 (last available year). Health care resources for managing severe GH patients aged 20-49 years, identified and quantified according to literature and expert' opinion, were valued through INHS tariffs (2025 values). One-way and scenario sensitivity analyses tested the robustness of the baseline findings.
Results: 375,553 pregnancies and 1928 episodes of severe GH needing hospitalization (0.51% of all pregnancies) were estimated for Italy in 2024. The overall average cost of managing a severe GH episode reaches €752.64. Inward hospitalization (€454.23) is the main cost-driver (60.04% of the total), as confirmed by one-way and scenario sensitivity analyses.
Conclusion: As reported in research conducted in other countries, inward hospitalization is both essential and the main cost-driver for the optimal management of severe GH. Outpatient programmes aimed at identifying and following-up GH patients before the disease requires hospitalization should be considered by INHS policymakers.
期刊介绍:
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.